Barinthus Biotherapeutics PLC Sponsored ADR (NASDAQ:BRNS) Short Interest Down 34.2% in July

Barinthus Biotherapeutics PLC Sponsored ADR (NASDAQ:BRNS) was the recipient of a significant decrease in short interest in the month of July. As of July 15th, there was short interest totaling 29,440 shares, a decrease of 34.2% from the June 30th total of 44,712 shares. Approximately 0.1% of the shares of the stock are sold short. Based on an average daily volume of 59,063 shares, the short-interest ratio is presently 0.5 days.

Institutional Inflows and Outflows

Institutional investors have recently modified their holdings of the stock. Rangeley Capital LLC lifted its position in shares of Barinthus Biotherapeutics by 88.8% during the 1st quarter. Rangeley Capital LLC now owns 159,465 shares of the company’s stock valued at $91,000 after acquiring an additional 75,024 shares during the last quarter. Renaissance Technologies LLC grew its holdings in shares of Barinthus Biotherapeutics by 115.8% in the 4th quarter. Renaissance Technologies LLC now owns 143,100 shares of the company’s stock worth $100,000 after acquiring an additional 76,800 shares during the last quarter. Finally, Baird Financial Group Inc. raised its position in shares of Barinthus Biotherapeutics by 108.2% during the second quarter. Baird Financial Group Inc. now owns 192,461 shares of the company’s stock worth $179,000 after purchasing an additional 100,000 shares during the period. Institutional investors own 25.20% of the company’s stock.

Barinthus Biotherapeutics Trading Up 0.1%

NASDAQ:BRNS opened at $0.56 on Friday. The company has a 50-day moving average of $0.65 and a 200-day moving average of $0.65. The firm has a market cap of $22.79 million, a price-to-earnings ratio of -0.43 and a beta of -0.41. Barinthus Biotherapeutics has a twelve month low of $0.51 and a twelve month high of $1.83.

Barinthus Biotherapeutics (NASDAQ:BRNS) last released its earnings results on Thursday, April 30th. The company reported ($0.14) EPS for the quarter, topping analysts’ consensus estimates of ($0.28) by $0.14.

Wall Street Analyst Weigh In

Separately, Weiss Ratings upgraded Barinthus Biotherapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Tuesday, July 21st. One equities research analyst has rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of “Hold” and a consensus target price of $4.00.

About Barinthus Biotherapeutics

Barinthus Biotherapeutics plc, a clinical-stage biopharmaceutical company, engages in development of novel T cell immunotherapeutic candidates designed to guide the immune system to overcome chronic infectious diseases, autoimmunity, and cancer. The company's development pipeline includes VTP-300, an immunotherapeutic candidate under phase 2 studies as a potential component of a functional cure for chronic hepatitis B virus (HBV) infection; VTP-200, a non-surgical product candidate under phase 2 studies for treating persistent high-risk human papillomavirus (HPV) infection; VTP-1000, an autoimmune preclinical candidate designed to treat patients with celiac disease; VTP-1100 product candidate to target HPV16+ cancers; and VTP-850/850, a second-generation immunotherapeutic candidate under phase 2 studies to treat recurrent prostate cancer.